Posted in Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority April 14, 2026 Pharmaceutical Technology MSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan’s BLA to treat ES-SCLC. RegulatoryOncologyRead full story